Mylan N.V. (NASDAQ:
MYL)
— Several analysts have raised their earnings estimates and price
targets for MYL stock following the company’s Q4 report last week. The
leading maker of generic pharmaceuticals delivered better-than-expected
earnings and upbeat 2015 guidance.
On March 3, S&P Capital IQ increased its 2015 EPS estimate to
$4.15 from $4.06. Its analysts maintained their “buy” rating on MYL
stock and raised their price target to $66 from $64.
Morgan Stanley (NYSE:
MS)
analyst David Risinger noted that MYL stock has one of the lowest
multiples in the industry. He placed an “overweight” rating on shares
with a price target of $67.
Mylan completed its acquisition of the non-U.S. developed markets generic unit of
Abbott Laboratories (NYSE:
ABT)
in late February. The deal added roughly $2 billion in annual revenue
and allowed the company to relocate its headquarters to the Netherlands.
Management expects this move will lower the company’s tax rate from 25%
to 20%-21% after the first year and to the high teens afterward.
Capital IQ said it sees Mylan making additional acquisitions this year.
Technically, MYL stock has been on a steady ascent since it broke
from a three-year consolidation in 2012 at about $25. Since then, shares
have advanced from a series of consolidations following buy signals
from my proprietary indicator, the Collins-Bollinger Reversal (CBR).
These advances have been accompanied by high volume, like the break in
October.
Last week, MYL stock broke above its 50-day moving average at $55.61,
but retreated on Friday, falling below the breakout point due to a
round of profit-taking in the broader market. This pullback could
provide an excellent opportunity to purchase shares of this well-managed
pharmaceutical company.
Buy MYL stock under $54. My trading target is $64, which would result
in a gain of 19%; however, long-term investors may want to hold shares
for a much higher return.
Please share this article
.jpg)
